Cargando…
The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies
PURPOSE: Fluoropyrimidine plus platinum (FP) is currently the standard treatment for esophageal cancer (EC). In recent years, taxane-based chemotherapy has also been used and has shown good efficacy in EC. This study aims to investigate the advantages of taxane-based over FP chemotherapy, as well as...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368118/ https://www.ncbi.nlm.nih.gov/pubmed/30787595 http://dx.doi.org/10.2147/DDDT.S189514 |
_version_ | 1783393926640566272 |
---|---|
author | Wang, Tao Yu, Jie Liu, Min Chen, Yanliang Zhu, Caiyun Lu, Lin Wang, Mingzhu Min, Lingfeng Liu, Xinxin Zhang, Xizhi Gubat, Johannes A Chen, Yong |
author_facet | Wang, Tao Yu, Jie Liu, Min Chen, Yanliang Zhu, Caiyun Lu, Lin Wang, Mingzhu Min, Lingfeng Liu, Xinxin Zhang, Xizhi Gubat, Johannes A Chen, Yong |
author_sort | Wang, Tao |
collection | PubMed |
description | PURPOSE: Fluoropyrimidine plus platinum (FP) is currently the standard treatment for esophageal cancer (EC). In recent years, taxane-based chemotherapy has also been used and has shown good efficacy in EC. This study aims to investigate the advantages of taxane-based over FP chemotherapy, as well as discuss its drawbacks, in the treatment of EC. PATIENTS AND METHODS: A literature search was done for studies comparing clinical outcomes between taxane-based and FP chemotherapy in EC. Pooled analyses were performed to compare the efficacy and grade 3/4 adverse events in patients who received neoadjuvant chemotherapy (NACT), neoadjuvant chemoradiotherapy (NACRT), or definitive chemoradiotherapy (dCRT). Subgroup analyses were also conducted in esophageal squamous cell carcinoma (ESCC). RESULTS: Thirty-one studies with a total of 3,912 patients were included in the analysis. Better long-term survival was found in patients who received taxane-based NACT (progression-free survival (PFS): pooled HR=0.58, P=0.0008; and overall survival (OS): pooled HR=0.50, P<0.00001) and dCRT (PFS: pooled HR=0.75, P<0.0001). In NACRT, taxane-based treatment and FP showed similar efficacy. In ESCC patients, taxane-based treatment showed better OS (NACT: pooled HR=0.57, P=0.02; NACRT: pooled HR=0.51, P=0.03; and dCRT: pooled HR=0.73, P<0.0001) than FP chemotherapy. Furthermore, taxane-based therapy also showed a better short-term response (complete response (CR), objective response rate (ORR), disease control rate (DCR), or pathologic complete response (pCR). However, taxane-based therapy was significantly correlated with a higher incidence of grade 3/4 leukopenia, neutropenia, and diarrhea. CONCLUSION: Compared to FP, taxane-based therapy produced better clinical response and outcomes in EC patients receiving NACT or dCRT, and in all types of therapy in patients with ESCC. Taxane-based treatment is associated with more frequent toxicity. |
format | Online Article Text |
id | pubmed-6368118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63681182019-02-20 The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies Wang, Tao Yu, Jie Liu, Min Chen, Yanliang Zhu, Caiyun Lu, Lin Wang, Mingzhu Min, Lingfeng Liu, Xinxin Zhang, Xizhi Gubat, Johannes A Chen, Yong Drug Des Devel Ther Original Research PURPOSE: Fluoropyrimidine plus platinum (FP) is currently the standard treatment for esophageal cancer (EC). In recent years, taxane-based chemotherapy has also been used and has shown good efficacy in EC. This study aims to investigate the advantages of taxane-based over FP chemotherapy, as well as discuss its drawbacks, in the treatment of EC. PATIENTS AND METHODS: A literature search was done for studies comparing clinical outcomes between taxane-based and FP chemotherapy in EC. Pooled analyses were performed to compare the efficacy and grade 3/4 adverse events in patients who received neoadjuvant chemotherapy (NACT), neoadjuvant chemoradiotherapy (NACRT), or definitive chemoradiotherapy (dCRT). Subgroup analyses were also conducted in esophageal squamous cell carcinoma (ESCC). RESULTS: Thirty-one studies with a total of 3,912 patients were included in the analysis. Better long-term survival was found in patients who received taxane-based NACT (progression-free survival (PFS): pooled HR=0.58, P=0.0008; and overall survival (OS): pooled HR=0.50, P<0.00001) and dCRT (PFS: pooled HR=0.75, P<0.0001). In NACRT, taxane-based treatment and FP showed similar efficacy. In ESCC patients, taxane-based treatment showed better OS (NACT: pooled HR=0.57, P=0.02; NACRT: pooled HR=0.51, P=0.03; and dCRT: pooled HR=0.73, P<0.0001) than FP chemotherapy. Furthermore, taxane-based therapy also showed a better short-term response (complete response (CR), objective response rate (ORR), disease control rate (DCR), or pathologic complete response (pCR). However, taxane-based therapy was significantly correlated with a higher incidence of grade 3/4 leukopenia, neutropenia, and diarrhea. CONCLUSION: Compared to FP, taxane-based therapy produced better clinical response and outcomes in EC patients receiving NACT or dCRT, and in all types of therapy in patients with ESCC. Taxane-based treatment is associated with more frequent toxicity. Dove Medical Press 2019-02-05 /pmc/articles/PMC6368118/ /pubmed/30787595 http://dx.doi.org/10.2147/DDDT.S189514 Text en © 2019 Wang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Wang, Tao Yu, Jie Liu, Min Chen, Yanliang Zhu, Caiyun Lu, Lin Wang, Mingzhu Min, Lingfeng Liu, Xinxin Zhang, Xizhi Gubat, Johannes A Chen, Yong The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies |
title | The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies |
title_full | The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies |
title_fullStr | The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies |
title_full_unstemmed | The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies |
title_short | The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies |
title_sort | benefit of taxane-based therapies over fluoropyrimidine plus platinum (fp) in the treatment of esophageal cancer: a meta-analysis of clinical studies |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368118/ https://www.ncbi.nlm.nih.gov/pubmed/30787595 http://dx.doi.org/10.2147/DDDT.S189514 |
work_keys_str_mv | AT wangtao thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT yujie thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT liumin thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT chenyanliang thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT zhucaiyun thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT lulin thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT wangmingzhu thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT minlingfeng thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT liuxinxin thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT zhangxizhi thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT gubatjohannesa thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT chenyong thebenefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT wangtao benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT yujie benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT liumin benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT chenyanliang benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT zhucaiyun benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT lulin benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT wangmingzhu benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT minlingfeng benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT liuxinxin benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT zhangxizhi benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT gubatjohannesa benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies AT chenyong benefitoftaxanebasedtherapiesoverfluoropyrimidineplusplatinumfpinthetreatmentofesophagealcancerametaanalysisofclinicalstudies |